ArticleNature aging2024
Integration of polygenic and gut metagenomic risk prediction for common diseases.
Article in Nature aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Cross-cohort analysis identifies shared gut microbial signatures and validates microbial risk scores for colorectal cancer.Journal of translational medicine · 2025Pooled it
- Constructing Genetic Risk Scores: Robust Bayesian Approach through Projected Summary Statistics and Flexible Shrinkage.Journal of the American Statistical Association · 2026Article
- Prostate Cancer at the Microbial Crossroads: Illuminating a New Frontier in Precision Medicine.The world journal of men's health · 2026Review
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Duodenal Fluid Microbiome Diversity and Pancreatic Cyst Status Among Patients Undergoing Pancreatic Surveillance.Gastro hep advances · 2026Article
- The gut microbiota-aromatic amino acid axis in cardiovascular disease: pathophysiological roles, translational biomarkers, and therapeutic targeting.Frontiers in cardiovascular medicine · 2026Review
- Prediction of Episodic Memory With Multiomics Scores.Biological psychiatry global open science · 2026Article
- Beyond the diagnostic threshold: paradigm shift in laboratory medicine from passive reaction to predictive capability.Frontiers in medicine · 2026Article
- First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study.Gut microbes · 2025Article
- Relationships among host genetics, gut microbiota, and asthma in US Hispanic/Latino adults.Nature communications · 2025Article
- Gut microbiota and urological cancers: from microecological imbalance to potential for precision therapy.Discover oncology · 2025Review
- Live Biotherapeutic Products for Metabolic Diseases: Development Strategies, Challenges, and Future Directions.Journal of microbiology and biotechnology · 2025Review
- Food substances alter gut resistome: Mechanisms, health impacts, and food components.Comprehensive reviews in food science and food safety · 2025Review
- Getting to the Heart of the Matter: Exploring the Intersection of Cardiovascular Disease, Sex and Race and How Exercise, and Gut Microbiota Influence these Relationships.Reviews in cardiovascular medicine · 2025Review
- Reprogramming prostate cancer through the microbiome.Frontiers in medicine · 2025Review
- Microbiome-mediated crosstalk between T2DM and MASLD: a translational review focused on function.Frontiers in endocrinology · 2025Review
- Alterations in gut microbiota characteristics along a type 2 diabetes risk gradient linked with family history.Gut microbes reports · 2025Article
- The oral-gut microbiota axis in cardiovascular diseases: mechanisms, therapeutic targets, and translational challenges.Frontiers in cellular and infection microbiology · 2025Review
- Unlocking the future of complex human diseases prediction: multi-omics risk score breakthrough.Frontiers in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
Abstract
Multiomics has shown promise in noninvasive risk profiling and early detection of various common diseases. In the present study, in a prospective population-based cohort with ~18 years of e-health record follow-up, we investigated the incremental and combined value of genomic and gut metagenomic risk assessment compared with conventional risk factors for predicting incident coronary artery disease (CAD), type 2 diabetes (T2D), Alzheimer disease and prostate cancer. We found that polygenic risk scores (PRSs) improved prediction over conventional risk factors for all diseases. Gut microbiome scores improved predictive capacity over baseline age for CAD, T2D and prostate cancer. Integrated risk models of PRSs, gut microbiome scores and conventional risk factors achieved the highest predictive performance for all diseases studied compared with models based on conventional risk factors alone. The present study demonstrates that integrated PRSs and gut metagenomic risk models improve the predictive value over conventional risk factors for common chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.